Ocera Therapeutics' P2P Acquisition

Ocera Therapeutics raised a round of funding on December 12, 2017. Investors include Mallinckrodt.

Ocera Therapeutics is focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases. The company's portfolio consists of OCR-002 and AST-120. OCR-002 is an a…

Articles about Ocera Therapeutics' P2P Acquisition: